Recent Updates
Recently added Catalysts
LONA Positive Sentiment

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: LeonaBio is set to present findings on lasofoxifene for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer at DAVA Oncology’s summit. The company is on schedule to complete enrollment for the Phase 3 ELAINE-3 clinical trial by the end of 2026, with expected topline data in the second half of 2027.

Market Sentiment Analysis

POSITIVE FACTORS

  • LeonaBio is advancing its clinical trial for lasofoxifene.
  • The Phase 3 ELAINE-3 trial is on track for enrollment completion.
  • Topline data is expected to provide insights in 2027.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~7 mo
Medium dilution risk
Lead asset
ATH-1017
Phase 2 · Alzheimer Disease

Full Press Release Details

On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for

Frequently Asked Questions

What is lasofoxifene used for?

Lasofoxifene is being developed for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

When will the ELAINE-3 trial complete enrollment?

The Phase 3 ELAINE-3 clinical trial is on track to complete enrollment by 4Q 2026.

When is the topline data expected?

Topline data from the ELAINE-3 trial is expected in the second half of 2027.

Where will LeonaBio present its findings?

LeonaBio will present findings at DAVA Oncology’s 4th Summit on Breast Cancer.

ShareAdd on Google
Tags: LONA Viatris Investor Conferences Healthcare LeonaBio Lasofoxifene ER-positive HER2-negative ESR1-mutated
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$68M liquidity · $7M/mo burn
~7 mo
Medium dilution risk
Lead asset
ATH-1017Phase 2
Alzheimer Disease →